Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 2 |
Descriptor
| Autism | 2 |
| Behavior Change | 2 |
| Children | 2 |
| Drug Therapy | 2 |
| Adolescents | 1 |
| Aggression | 1 |
| Behavior Problems | 1 |
| Check Lists | 1 |
| Communication Skills | 1 |
| Control Groups | 1 |
| Experimental Groups | 1 |
| More ▼ | |
Author
| Aman, Michael | 1 |
| Berk, Michael | 1 |
| Brown, Ellie | 1 |
| Byrne, Linda K. | 1 |
| Dean, Olivia M. | 1 |
| Dodd, Seetal | 1 |
| Gray, Kylie | 1 |
| Hough, David | 1 |
| Karcher, Keith | 1 |
| Kent, Justine M. | 1 |
| Kushner, Stuart | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
| Australia | 1 |
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
| Developmental Behavior… | 1 |
| Obsessive Compulsive Scale | 1 |
| Social Responsiveness Scale | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkDean, Olivia M.; Gray, Kylie; Dodd, Seetal; Villagonzalo, Kristi-Ann; Brown, Ellie; Tonge, Bruce; Berk, Michael; Byrne, Linda K. – Journal of Intellectual & Developmental Disability, 2019
Background: Traditional treatment for the behavioural symptoms in autism spectrum disorder (ASD) remains unsatisfactory. There is an urgent need for new, biologically relevant therapies that target both the core and comorbid symptoms that children may experience. This article builds on research previously published by the authors. Method: We…
Descriptors: Autism, Pervasive Developmental Disorders, Intervention, Children
Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David – Journal of Autism and Developmental Disorders, 2013
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…
Descriptors: Drug Therapy, Children, Adolescents, Autism
